Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Blog

Fast-paced Momentum Stock Synchronoss (SNCR) Is Still Trading at a Bargain
Fast-paced Momentum Stock Synchronoss (SNCR) Is Still Trading at a Bargain

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks

Fast-paced Momentum Stock SSAB (SSAAY) Is Still Trading at a Bargain
Fast-paced Momentum Stock SSAB (SSAAY) Is Still Trading at a Bargain

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks

CRA International Shares Barely Move Since Q1 Earnings Beat
CRA International Shares Barely Move Since Q1 Earnings Beat

CRA International, Inc. CRAI reported impressive first-quarter 2025 results, with earnings and revenues beating the Zacks Consensus Estimate. The stock has barely moved since the earnings release

Zacks Investment Ideas feature highlights: Quanta Services, BWX Technologies and Constellation Energy
Zacks Investment Ideas feature highlights: Quanta Services, BWX Technologies and Constellation Energy

For Immediate Release

Chicago, IL – May 5, 2025– Today, Zacks Investment Ideas feature highlights Quanta Services PWR, BWX Technologies, Inc. BWXT and Constellation Energy CEG.

Top Nuclear Energy

Is CVNA Stock a Buy Pre-Q1 Earnings? Key Metrics to Watch
Is CVNA Stock a Buy Pre-Q1 Earnings? Key Metrics to Watch

Carvana CVNA is slated to release first-quarter 2025 results on Wednesday, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 75

GM vs. TSLA: Which Auto Giant is a Better Investment Option Now?Photo, wide shot, wide-angle lens, soft focus,  Car rental company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Edward Burtynsky: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-C39HK7mRtkD4E8dIGhNKdJKJ.png?st=2023-05-14T13%3A30%3A04Z&se=2023-05-14T15%3A30%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-13T20%3A57%3A44Z&ske=2023-05-14T20%3A57%3A44Z&sks=b&skv=2021-08-06&sig=c7kEiWtHt1KibrlL7jP9uEmEuV%2BuAnv1nRBACXoedSk%3D
GM vs. TSLA: Which Auto Giant is a Better Investment Option Now?

A fresh wave of auto tariffs is rattling the U.S. auto industry — this time targeting imported parts rather than fully assembled vehicles. While previous levies largely spared American-made cars

Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls
Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls

Henry Schein, Inc. HSIC registered adjusted earnings per share (EPS) of $1.15 in the first quarter of 2025, up 4.5% from the year-ago period’s figure. The figure topped the Zacks Consensus Estimate

Cummins (CMI) Surpasses Q1 Earnings and Revenue Estimates
Cummins (CMI) Surpasses Q1 Earnings and Revenue Estimates

Cummins (CMI) came out with quarterly earnings of $5.96 per share, beating the Zacks Consensus Estimate of $4.82 per share. This compares to earnings of $5.10 per share a year ago. These figures are

Tyson Foods (TSN) Surpasses Q2 Earnings Estimates
Tyson Foods (TSN) Surpasses Q2 Earnings Estimates

Tyson Foods (TSN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.62 per share a year ago. These figures

Here's How Much a $1000 Investment in Celestica Made 10 Years Ago Would Be Worth Today
Here's How Much a $1000 Investment in Celestica Made 10 Years Ago Would Be Worth Today

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across

If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now
If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

Here's How Much a $1000 Investment in Microsoft Made 10 Years Ago Would Be Worth TodayPhoto, wide shot, wide-angle lens,  Consumer electronics manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://img.theapi.app/temp/d8a4268f-c982-4aa8-a09e-f9ee1db62f57.png
Here's How Much a $1000 Investment in Microsoft Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

Here's How Much a $1000 Investment in Heico Corporation Made 10 Years Ago Would Be Worth Today
Here's How Much a $1000 Investment in Heico Corporation Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and

If You Invested $1000 in Agnico Eagle Mines a Decade Ago, This is How Much It'd Be Worth Now
If You Invested $1000 in Agnico Eagle Mines a Decade Ago, This is How Much It'd Be Worth Now

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago. These figures

Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in FocusPhoto, wide shot, wide-angle lens,  Heavy machinery, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Edward Burtynsky: https://img.midjourneyapi.xyz/temp/c15253b0-7330-4605-a666-66954eaf6715.png
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus

The three most widely followed indexes in the United States have ended the past trading week on a positive note. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average have gained by

S&P 500 Achieves a Milestone After Two Decades - 5 Top Picks
S&P 500 Achieves a Milestone After Two Decades - 5 Top Picks

The S&P 500 Index has been able to recoup all losses suffered due to the Trump administration’s tariff-led market mayhem at a lightning speed. On May 2, the broad-market index recorded a nine-day

5 Momentum Stocks to Buy for May After a Mixed April
5 Momentum Stocks to Buy for May After a Mixed April

Wall Street saw severe volatility and almost day-to-day fluctuations in both directions in April. Finally, U.S. stock markets ended mixed last month. The S&P 500 and the Dow fell 3.2% and 0.8%

Top Wide-Moat Stocks to Invest in for Long-Term Growth
Top Wide-Moat Stocks to Invest in for Long-Term Growth

An updated edition of the March 12, 2025, article.

In the business world, the concept of a wide moat refers to companies with strong, durable competitive advantages that protect them from rivals

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1Photo, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago. These

New Strong Buy Stocks for May 5th
New Strong Buy Stocks for May 5th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

GeneDx Holdings Corp. WGS: This genomics-related diagnostic and information services company has seen the Zacks Consensus

Buy These Top-Ranked 5 Stocks to Play an Earnings Beat
Buy These Top-Ranked 5 Stocks to Play an Earnings Beat

It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago. These

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago. These figures

Flex Gearing Up to Report Q4 Earnings: Here's What to Expect
Flex Gearing Up to Report Q4 Earnings: Here's What to Expect

Flex Ltd. FLEX is scheduled to report fourth-quarter fiscal 2025 results on May 7, before the market opens.

The Zacks Consensus Estimate for fiscal fourth-quarter revenues is pegged at $6.23